Monte Rosa Therapeutics
Latest round
- Series C
Last raised
- Mar 2021
Total raised
- $181M
Investors
- 16
About Monte Rosa Therapeutics
Founded in 2018 and Based in Massachusetts, US, Monte Rosa Therapeutics, Inc. operates as a biotechnology company that uses a protein degradation platform for developing cancer therapeutics.5 million as of March 2021 and In June 2021, Monte Rosa Therapeutics, Inc.7 million shares at USD 19 per share on the Nasdaq under the ticker symbol "GLUE". As of 2021, the company's CEO is Markus Warmuth. Monte Rosa Therapeutics, Inc. develops molecular glues to treat cancer and other autoimmune diseases. The company also provides a protein degradation platform, called QuEEN to rationally design small molecules which reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company plans to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities to rationally design and develop small molecule degraders.
Who invested in Monte Rosa Therapeutics
16 investors across 4 rounds
See all investors in Monte Rosa Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Monte Rosa Therapeutics
Who invested in Monte Rosa Therapeutics?
Monte Rosa Therapeutics has 16 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Monte Rosa Therapeutics raised?
Monte Rosa Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Monte Rosa Therapeutics last raise money?
Monte Rosa Therapeutics's most recent round on record is a Series C, in Mar 2021.
What does Monte Rosa Therapeutics do?
Founded in 2018 and Based in Massachusetts, US, Monte Rosa Therapeutics, Inc.
Where is Monte Rosa Therapeutics headquartered?
Monte Rosa Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like Monte Rosa Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Monte Rosa Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Monte Rosa Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.